Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine and the Department of Medicine, Veterans Administration Healthcare System, Palo Alto, CA, U.S.A.
Clin Sci (Lond). 2018 Sep 5;132(17):1925-1935. doi: 10.1042/CS20171157. Print 2018 Sep 14.
By 2050, there will be over 1.6 billion adults aged 65 years and older, making age-related diseases and conditions a growing public health concern. One of the leading causes of death in the ageing population is pathogenic infections (e.g. influenza, ). This age-dependent susceptibility to infection has been linked to a reduced ability of the ageing immune system to mount protective responses against infectious pathogens, as well as to vaccines against these pathogens. The primary immune response that promotes protection is the production of antibodies by B cells - a response that is directly mediated by T follicular helper (T) cells within germinal centers (GCs) in secondary lymphoid tissues. In this review, we will summarize the current knowledge on the development and functionality of T cells, the use of circulating T (cT) cells as vaccine biomarkers, and the influence of age on these processes. Moreover, we will discuss the strategies for overcoming T cell dysfunction to improve protective antibody responses in the ageing human population.
到 2050 年,将有超过 16 亿 65 岁及以上的成年人,使与年龄相关的疾病和状况成为日益严重的公共卫生关注问题。在老年人群中,导致死亡的主要原因之一是病原性感染(例如流感)。这种与年龄相关的易感染性与衰老免疫系统对感染性病原体产生保护性反应的能力下降有关,也与针对这些病原体的疫苗有关。促进保护的主要免疫反应是 B 细胞产生抗体——这一反应直接由次级淋巴组织中的生发中心(GC)内的滤泡辅助 T(Tfh)细胞介导。在这篇综述中,我们将总结 T 细胞的发育和功能、循环 T(cT)细胞作为疫苗生物标志物的用途以及年龄对这些过程的影响的现有知识。此外,我们将讨论克服 T 细胞功能障碍的策略,以改善老年人群的保护性抗体反应。